Follicular Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EZH2 p.Y646N | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.Y646F | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.Y646H | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.Y646S | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.Y646C | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.A862G | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | EZH2 p.A692V | Follicular Lymphoma | Tazemetostat | FDA |
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Rituximab | HC |
| Sensitivity (+) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Prednisolone, Rituximab, Vincristine | HC |